Objective:To investigate the iodine nutrition status of key populations in Linfen City, scientifically evaluate the current situation of iodine deficiency disorders prevention and control, and provide scientific basis for timely and targeted prevention and control of iodine deficiency disorders.Methods:According to the requirements of the "Monitoring Plan for Iodine Deficiency Disorders in Shanxi Province", from 2019 to 2023, monitoring was conducted annually in 17 counties (cities, districts, hereinafter referred to as county) under the jurisdiction of Linfen City. Each county was divided into five districts: east, west, south, north, and middle. One township/street was selected from each district, and 40 students aged 8 to 10 years from one primary school and 20 pregnant women were selected from each township/street as survey subjects. Household edible salt samples and one random urine samples were collected to test salt iodine and urinary iodine levels, and thyroid volume was measured on some children.Results:From 2019 to 2023, a total of 25 695 household edible salt samples were collected from children and pregnant women in 17 counties of Linfen City, with an average salt iodine range of 22.20 - 23.80 mg/kg. The qualified iodized salt consumption rates were 90.99% (4 674/5 137), 94.75% (4 889/5 160), 95.27% (4 889/ 5 132), 94.50% (4 843/5 125), and 95.82% (4 926/5 141), respectively; the iodized salt coverage rates were > 95%, and the qualified iodized salt rates were > 90%. And all the three showed an increasing trend year by year (χ 2trend = 56.31, 110.92, 137.24, P < 0.001). A total of 17 145 urine samples were collected from children, and the medians urinary iodine from 2019 to 2023 were 213.03, 187.40, 185.07, 190.70, and 189.30 μg/L, respectively. There were 8, 8, 9, 5, and 11 counties with appropriate iodine for children in each year, 0, 1, 0, 2, and 1 county with excessive iodine, and no county with iodine deficiency. A total of 8 548 urine samples were collected from pregnant women. The medians urinary iodine for pregnant women from 2019 to 2023 were 181.59, 187.40, 194.40, 187.25, and 187.10 μg/L, respectively. There were 14, 13, 15, 15, and 16 counties with appropriate iodine levels for pregnant women in each year, and 2, 4, 1, 0, and 1 county with iodine deficiency. A total of 5 670 children were examined for thyroid. The thyroid enlargement rates in children from 2019 to 2023 were 1.57%, 2.94%, 2.86%, 3.80%, and 2.82%, respectively. From 2019 to 2023, there were no new cases of endemic cretinism in Linfen City, and the thyroid enlargement rates in children were < 5%. Conclusions:From 2019 to 2023, all 17 counties in Linfen City are in a state of eliminating iodine deficiency disorders, and children and pregnant women are generally at an appropriate iodine and exceeding the appropriate iodine level. We should continue to strengthen the monitoring of iodine nutrition for key populations, carry out health education on scientific iodine supplementation, and effectively consolidate the achievements of iodine deficiency disorders prevention and control.

Objective:To investigate the impact of receptor-interacting protein kinase 3 (RIPK3) on major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI), as well as the predictive performance of RIPK3 combined with traditional cardiovascular risk factors.Methods:This study was a single-center prospective cohort study. It included patients with AMI who underwent PCI at Peking Union Medical College Hospital between September 2017 and November 2017. Baseline clinical data were collected, and plasma samples were obtained 6 hours after PCI to measure RIPK3 levels. Follow-up was conducted via outpatient visits or phone calls to record the occurrence of MACE, including cardiovascular death, hospitalization for heart failure, and vascular events (recurrent AMI or stroke). The predictive performance of RIPK3, traditional cardiovascular risk factors and their combination for MACE was compared using receiver operating characteristic (ROC) curves. Patients were divided into low- and high-RIPK3 level groups based on the optimal cutoff value of RIPK3. Multivariate Cox proportional hazards regression analysis was used to assess the impact of RIPK3 levels on MACE after PCI in AMI patients. Kaplan-Meier survival curves were plotted, and the log-rank test was used to compare MACE incidence between the low-and high-RIPK3 groups.Results:A total of 103 AMI patients who underwent PCI were included, aged 63.0 (56.0, 69.0) years, and 83 (80.6%) were male. The follow-up time was 5.17 (2.81, 5.17) years, during which 44 patients (42.7%) experienced MACE. The ROC curve analysis showed that the area under the curve ( AUC) for traditional cardiovascular risk factors was 0.68 (95% CI: 0.58-0.78), while the AUC for plasma RIPK3 was 0.72 (95% CI: 0.62-0.82). The combined AUC for traditional risk factors and RIPK3 was 0.75 (95% CI: 0.65-0.85). Multivariate Cox proportional hazards regression analysis indicated that plasma RIPK3 level is greater than or equal to the optimal cutoff value of 440.9 μg/L ( HR=3.31, 95% CI: 1.53-8.30, P=0.005) was an independent risk factor for MACE in AMI patients after PCI. Kaplan-Meier survival analysis demonstrated that the high-RIPK3 group had a significantly higher risk of MACE after PCI compared to the low-RIPK3 group (log-rank P=0.006). Conclusions:Elevated plasma RIPK3 level is an independent risk factor for MACE in AMI patients after PCI. Plasma RIPK3 combined with traditional cardiovascular risk factors can more effectively predict the occurrence of MACE in AMI patients after PCI. AMI patients with RIPK3≥440.9 μg/L have a higher risk of MACE after PCI.

Objective:To investigate the iodine nutrition status of key populations in Linfen City, scientifically evaluate the current situation of iodine deficiency disorders prevention and control, and provide scientific basis for timely and targeted prevention and control of iodine deficiency disorders.Methods:According to the requirements of the "Monitoring Plan for Iodine Deficiency Disorders in Shanxi Province", from 2019 to 2023, monitoring was conducted annually in 17 counties (cities, districts, hereinafter referred to as county) under the jurisdiction of Linfen City. Each county was divided into five districts: east, west, south, north, and middle. One township/street was selected from each district, and 40 students aged 8 to 10 years from one primary school and 20 pregnant women were selected from each township/street as survey subjects. Household edible salt samples and one random urine samples were collected to test salt iodine and urinary iodine levels, and thyroid volume was measured on some children.Results:From 2019 to 2023, a total of 25 695 household edible salt samples were collected from children and pregnant women in 17 counties of Linfen City, with an average salt iodine range of 22.20 - 23.80 mg/kg. The qualified iodized salt consumption rates were 90.99% (4 674/5 137), 94.75% (4 889/5 160), 95.27% (4 889/ 5 132), 94.50% (4 843/5 125), and 95.82% (4 926/5 141), respectively; the iodized salt coverage rates were > 95%, and the qualified iodized salt rates were > 90%. And all the three showed an increasing trend year by year (χ 2trend = 56.31, 110.92, 137.24, P < 0.001). A total of 17 145 urine samples were collected from children, and the medians urinary iodine from 2019 to 2023 were 213.03, 187.40, 185.07, 190.70, and 189.30 μg/L, respectively. There were 8, 8, 9, 5, and 11 counties with appropriate iodine for children in each year, 0, 1, 0, 2, and 1 county with excessive iodine, and no county with iodine deficiency. A total of 8 548 urine samples were collected from pregnant women. The medians urinary iodine for pregnant women from 2019 to 2023 were 181.59, 187.40, 194.40, 187.25, and 187.10 μg/L, respectively. There were 14, 13, 15, 15, and 16 counties with appropriate iodine levels for pregnant women in each year, and 2, 4, 1, 0, and 1 county with iodine deficiency. A total of 5 670 children were examined for thyroid. The thyroid enlargement rates in children from 2019 to 2023 were 1.57%, 2.94%, 2.86%, 3.80%, and 2.82%, respectively. From 2019 to 2023, there were no new cases of endemic cretinism in Linfen City, and the thyroid enlargement rates in children were < 5%. Conclusions:From 2019 to 2023, all 17 counties in Linfen City are in a state of eliminating iodine deficiency disorders, and children and pregnant women are generally at an appropriate iodine and exceeding the appropriate iodine level. We should continue to strengthen the monitoring of iodine nutrition for key populations, carry out health education on scientific iodine supplementation, and effectively consolidate the achievements of iodine deficiency disorders prevention and control.

Objective:To investigate the impact of receptor-interacting protein kinase 3 (RIPK3) on major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI), as well as the predictive performance of RIPK3 combined with traditional cardiovascular risk factors.Methods:This study was a single-center prospective cohort study. It included patients with AMI who underwent PCI at Peking Union Medical College Hospital between September 2017 and November 2017. Baseline clinical data were collected, and plasma samples were obtained 6 hours after PCI to measure RIPK3 levels. Follow-up was conducted via outpatient visits or phone calls to record the occurrence of MACE, including cardiovascular death, hospitalization for heart failure, and vascular events (recurrent AMI or stroke). The predictive performance of RIPK3, traditional cardiovascular risk factors and their combination for MACE was compared using receiver operating characteristic (ROC) curves. Patients were divided into low- and high-RIPK3 level groups based on the optimal cutoff value of RIPK3. Multivariate Cox proportional hazards regression analysis was used to assess the impact of RIPK3 levels on MACE after PCI in AMI patients. Kaplan-Meier survival curves were plotted, and the log-rank test was used to compare MACE incidence between the low-and high-RIPK3 groups.Results:A total of 103 AMI patients who underwent PCI were included, aged 63.0 (56.0, 69.0) years, and 83 (80.6%) were male. The follow-up time was 5.17 (2.81, 5.17) years, during which 44 patients (42.7%) experienced MACE. The ROC curve analysis showed that the area under the curve ( AUC) for traditional cardiovascular risk factors was 0.68 (95% CI: 0.58-0.78), while the AUC for plasma RIPK3 was 0.72 (95% CI: 0.62-0.82). The combined AUC for traditional risk factors and RIPK3 was 0.75 (95% CI: 0.65-0.85). Multivariate Cox proportional hazards regression analysis indicated that plasma RIPK3 level is greater than or equal to the optimal cutoff value of 440.9 μg/L ( HR=3.31, 95% CI: 1.53-8.30, P=0.005) was an independent risk factor for MACE in AMI patients after PCI. Kaplan-Meier survival analysis demonstrated that the high-RIPK3 group had a significantly higher risk of MACE after PCI compared to the low-RIPK3 group (log-rank P=0.006). Conclusions:Elevated plasma RIPK3 level is an independent risk factor for MACE in AMI patients after PCI. Plasma RIPK3 combined with traditional cardiovascular risk factors can more effectively predict the occurrence of MACE in AMI patients after PCI. AMI patients with RIPK3≥440.9 μg/L have a higher risk of MACE after PCI.

Rifabutin(RBT) is a rifamycin derivative,like rifampicin(RIF),registered for the prophylaxis and treatment of mycobacterium avium complex (MAC)in patients with AIDS by FDA in 1992.Subsequently,the drug was approved by many other countries.But now,it is used not only in the prophlaxis and treatment of mycobacterium avium complex but also in the treatment of pulmonary tuberculosis and Helicobacter pylori.For its high lipophilic characteristic and weak inducing properties compare to other rifamycin derivative,it can be applied in treatment with many diseases successfully,especially when combine with other antibiotics,and can solve the problem of traditional antibiotics resistance and increase the clinical safety of combined medical treatment.This paper just shows the progress of clinical pharmacological study and related aspects on rifabutin in order to instruct prescription.